Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Sqz Biotech Completes Oversubscribed $72m Series C Financing
Venture Capital

Sqz Biotech Completes Oversubscribed $72m Series C Financing

by vcaonline.com posted 1week ago 8 views
SQZ Biotech Completes Oversubscribed $72 Million Series C FinancingSQZ advancing cell therapy pipeline toward clinical trials in multiple indications Company Board of Directors expands with addition of Marc Elia and Zafi Avnur, PhD WATERTOWN, Mass., August 8, 2018-- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing. New investors include Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group. Existing investors also participated and include Bridger Healthcare Partners, Global Health Science Fund, GV, JDRF T1D Fund, NanoDimension, and Polaris.